![]() "Technology has finally advanced enough to meet the unique regulatory and quality requirements of the pharma industry," said Angelo Stracquatanio, CEO & Co-founder of Apprentice. Collaborate better with external partners with shared digital access to production runs and workflows for batch review and signoff.Expedite new product introduction by digitally conducting technical transfer.Accelerate the drug product pipeline with centralized recipe management and optimization.Manage production across multiple internal and external manufacturing sites with real-time visibility.Using CMN, companies can now connect all sites together to view, manage, and accelerate the end-to-end drug production lifecycle. Tempo improves operations at the site level by coordinating the materials, equipment, recipes, and personnel needed to plan, execute, test, and release a batch from one shared system. ![]() As a result, pharma manufacturing is more decentralized than ever. Existing infrastructure built for traditional modalities is rapidly becoming capacity and capability constrained. Innovation in drug modalities like biologics and cell and gene therapies offer incredible new treatments but are meaningfully more complex and costly to produce. The Connected Manufacturing Network (CMN) is the newest addition to the company's product suite, the Tempo Manufacturing Cloud, and the first of its kind in-market. The leading cloud-native platform for pharma manufacturing execution also announced a $65 million investment led by new investor ICONIQ Growth, with meaningful participation from existing investors, Alkeon Capital Management and Insight Partners.Īnnouncing the Connected Manufacturing Network Apprentice.io, provider of one platform for life science manufacturers to turn molecules into medicine, today announced a new addition to the Tempo Manufacturing Cloud, the Connected Manufacturing Network.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |